Background: Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors (ICIs), leaving a gap in knowledge.
Research Question: What are the clinical outcomes of ICIs in patients with NSCLC and preexisting ILD?
Study Design And Methods: Systematic searches were conducted of PubMed, EMBASE, and Cochrane Library through April 2021 with no language or study design restrictions. Studies reporting the safety and efficacy data among patients with cancer and ILD receiving ICI therapy were collected. The primary end points were clinical efficacy to immunotherapy and the incidence of immune-related adverse events, especially for checkpoint inhibitor pneumonitis (CIP).
Results: A total of 179 patients in 10 studies were included. The pooled overall response rate (ORR) and pooled disease control rate (DCR) were 34% (95% CI, 20-47) and 66% (95% CI, 56-75), respectively. The ORR in patients with preexisting ILD was significantly higher than that in patients without ILD (OR, 1.99; 95% CI, 1.31-3.00). The DCR and progression-free survival in patients with preexisting ILD were not inferior to those without ILD (pooled OR, 1.46; 95% CI, 0.94-2.25 for DCR). The pooled incidences of any grade and grade 3 or higher CIP were 27% (95% CI, 17-37) and 15% (95% CI, 9-22) in patients with preexisting ILD, and 10% (95% CI, 6-13) and 4% (95% CI, 2-6) in patients without ILD. Meta-analysis found a significantly higher incidence rate of any grade and grade 3 or higher CIP in patients with NSCLC and preexisting ILD than in those patients without ILD (OR, 3.23 [95% CI, 2.06-5.06]; OR, 2.91 [95% CI, 1.47-5.74]).
Interpretation: Programmed cell death protein 1/programmed cell death ligand 1 inhibitors had favorable efficacy in NSCLC with preexisting ILD. CIP is frequent in patients with preexisting ILD who receive ICI therapy but is often mild and easily manageable. Clinicians should be cautious when using ICIs in patients with preexisting ILD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chest.2021.12.656 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy.
J Dermatolog Treat
December 2024
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Article Synopsis
- * A case study of a 69-year-old man highlighted respiratory issues after 18 months of treatment, revealing significant lung damage through medical imaging and biopsy, which pointed to immune cell involvement.
- * The findings emphasize the need for close lung monitoring in patients on biologic therapies, especially those with existing lung problems, as ixekizumab may lead to serious inflammatory responses.
Impact of docetaxel plus ramucirumab therapy on interstitial lung disease in recurrent advanced non-small cell lung cancer patients.
Transl Lung Cancer Res
October 2024
Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Article Synopsis
- A study was conducted to investigate the safety and effectiveness of docetaxel/ramucirumab (DOC/RAM) therapy in patients with advanced non-small cell lung cancer (NSCLC) who also had interstitial lung disease (ILD).
- The study found that 25% of patients with pre-existing ILD developed DOC/RAM-induced interstitial pneumonia, while no patients without ILD experienced this condition.
- Despite the increased incidence of pneumonia in those with ILD, the treatment did not significantly impact the overall treatment outcomes like objective response rate, progression-free survival, or overall survival.
A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease.
BMC Pulm Med
October 2024
Edinburgh Lung Fibrosis Clinic, Royal Infirmary of Edinburgh, Edinburgh, UK.
Background: Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.
Aim: To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.
Methods: A modified international 3-tier Delphi exercise was performed.
Drug-induced lung disease: a narrative review.
J Bras Pneumol
October 2024
. Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo - HCFMUSP - São Paulo (SP) Brasil.
Article Synopsis
- Drug-induced lung disease (DILD) happens when certain medicines harm the lungs, affecting between 3% and 5% of people with lung diseases.
- Symptoms can appear quickly after starting treatment and may range from not feeling sick at all to having serious breathing problems.
- To treat DILD, doctors usually stop the harmful medication and may give steroids, but the chances of recovery can be very different for each person and some cases can be very serious.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Lung Cancer
October 2024
Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan.
Article Synopsis
- The study aimed to assess the safety and efficacy of chemoimmunotherapy in patients with extensive-stage small-cell lung cancer (SCLC) who also had mild interstitial lung disease (ILD).
- In a trial with 21 patients, a low incidence of pneumonitis was observed, with a severe pneumonitis-free rate of 95.2% and only two patients experiencing pneumonitis during treatment.
- The findings suggest that chemoimmunotherapy could be a viable treatment option for these patients, with a median overall survival of 10.7 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!